James Rucker
Senior Clinical Lecturer at King's College London
Key Impact
Leads the Psychedelic Trials Group investigating psilocybin for treatment-resistant depression.
Background & Research
James Rucker is a consultant psychiatrist and leading trialist in the UK. He heads the Psychedelic Trials Group at the Institute of Psychiatry, Psychology & Neuroscience, where he conducts clinical trials on psilocybin, MDMA, and ketamine. His work focuses on integrating these pharmacological breakthroughs with psychotherapeutic frameworks for psychiatric recovery.
Collaboration Network
48 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Depressive DisordersSafety & Risk ManagementAnxiety DisordersTreatment-Resistant Depression (TRD)Substance Use Disorders (SUD)Major Depressive Disorder (MDD)Chronic PainPTSDHeadache Disorders (Cluster & Migraine)Palliative & End-of-Life DistressHealthy VolunteersSet & SettingPersonality & Trait FactorsObsessive-Compulsive Disorder (OCD)Alcohol Use Disorder (AUD)Medicinal Chemistry & Drug DevelopmentInterpersonal Functioning & Social ConnectednessPublic Health, Prevention & Behaviour ChangeAdolescentsTobacco/Nicotine Use Disorder (TUD)SchizophreniaOlder AdultsNeurocognitive DisordersMicrodosingPeripartumNeuroimaging & Brain MeasuresEquity and EthicsSuicidalityNeurological Injury